MedPath

Effect of Time-of-Day Administration of Amilodipine/Valsartan on Hypertention Control

Phase 3
Recruiting
Conditions
Stage II hypertension according to ACC/AHA2017 definition.
Essential (primary) hypertension
Registration Number
IRCT20240131060872N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Age range between 35-75
Absence of underlying disease such as no renal diseases, no diabetes mellitus, and no cardiovascular diseases
No previous history of hypertension treatment
Consent to enter the study

Exclusion Criteria

Having renal diseases
Having diabetes Mellitus
Having cardiovascular diseases including ischemic, non-ischemic, and heart failure

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.